Business
Tyra Biosciences Reports Third Quarter 2021 Financial Results and Highlights
-Successful completion of upsized $198.7 million initial public offering; cash and cash equivalents of $312.8 million as of September 30, 2021- -Nominated 2nd
About this update from Tyra Biosciences, Inc.
[{"type":"text","content":"-Successful completion of upsized $198.7 million initial public offering; cash and cash equivalents of $312.8 million as of September 30, 2021-\n -Nominated 2nd product candidate for clinical development, TYRA-200 (FGFR2 inhibitor), from its SNÅP platform-\n -Strengthened team with appointments of Esther van den Boom as Chief Financial Officer, John Healy as General Counsel, Allison Kemner as VP, Clinical Sciences and Operations, and Rehan Verjee as a member of the Board of Directors-\n\n\nCARLSBAD, Calif., Nov. 3, 2021 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today reported financial results for the quarter ended September 30, 2021 and highlighted recent corporate progress. \n\"2021 has been transformational for TYRA. We're pleased to have made meaningful progress across our business with important advancements in our programs, people and financial strategy,\" said Todd Harris, CEO of TYRA. \"With the capital raised in our IPO from top tier institutional investors, key additions to our leadership and board and the growth of our pipeline, TYRA is well-positioned to execute on our strategy of delivering next-generation therapies to patients with acquired tumor resistance.\"\nThird Quarter 2021 and Recent Corporate Highlights\nCompleted $198.7 Million Upsized Initial Public Offering. In September 2021, TYRA sold 12,420,000 shares of common stock in its initial public offering, which included the exercise in full by the underwriters of their option to purchase 1,620,000 additional shares of common stock, at a public offering price of $16.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by TYRA, were $198.7 million. Appointed Rehan Verjee to Board of Directors. Rehan Verjee, former President of EMD Serono and Global Head of the Innovative Medicine Franchises for Merck KGaA, was appointed to TYRA's Board of Directors. Strengthened Leadership. TYRA made key senior appointments including Esther van den Boom as Chief Financial Officer, John Healy as General Counsel, and Allison Kemner as Vice President, Clinical Sciences and Operations. Nominated 2nd Product Candidate for Clinical ...